Would you offer zolbetuximab in a non-Asian population?
Neither GLOW nor SPOTLIGHT showed a statistically significant improvement in PFS/OS for non-Asian subgroups. It is reasonable to suspect that any PFS/OS benefit was driven by the Asian populations in the study. Even if the studies were not fully powered for this subgroup analysis, the similar findings in both trials raise questions as to the external validity across all populations.
1 Answer
Mednet Member
Medical Oncology · IHA Hem Onc Consult
Answered on
Great question. Both studies suggested a discrepancy in benefits between white and Asian patients. However, these were subgroup analyses and neither study was powered to specifically detect a significant effect in white patients. Issues like this are frequently encountered in randomized clinical tri...
Join for free or sign in to see the full answer